NS 1546

Drug Profile

NS 1546

Latest Information Update: 22 Jan 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroSearch
  • Developer GlaxoSmithKline; NeuroSearch
  • Class Antidepressants; Nootropics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cognition disorders; Major depressive disorder

Most Recent Events

  • 22 Jan 1997 Discontinued-Preclinical for Cognition disorders (Unknown route)
  • 06 Jan 1997 Discontinued-Preclinical for Depression in Denmark (Unknown route)
  • 06 Jan 1997 Discontinued-Preclinical for Depression in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top